title: Use of the round window microcatheter in the treatment of Meniere's disease.
abstract: OBJECTIVE
  Transtympanic gentamicin is an increasingly popular treatment for Meniere's disease. The present report examines the 2-year follow-up of our first 27 patients with Meniere's disease treated with the use of microdose gentamicin through the Round Window Microcatheter. We applied the 1995 American Academy of Otolaryngology-Head and Neck Surgery criteria to this patient group to analyze the results of treatment.
  
  
  METHODS
  This study is an evaluation of consecutive patients with predetermined data collection on each patient.
  
  
  METHODS
  Patients with confirmed Meniere's disease underwent placement of the Round Window Microcatheter, which was filled with 10 mg/mL gentamicin, after placement into the round window niche was confirmed. Ten milligrams per milliliter of gentamicin was injected into the catheter by hand on two occasions after device placement in the first several patients. The remaining patients had continuous infusion of 10 mg/mL gentamicin at 1microL/h for the next 10 days. The catheter was removed 10 days after placement. All patients underwent an extensive set of hearing and vestibular tests on several occasions before, during, and after treatment.
  
  
  RESULTS
  In the patients in the study, vertigo was eliminated in 92.6%, with 3.7% of patients (1/27) demonstrating a mild permanent threshold shift in hearing. Tinnitus and pressure were significantly reduced in more than 65% of patients. Only one patient demonstrated a reduction of vestibular function after treatment.
  
  
  CONCLUSIONS
  Results of this study on this group of patients indicate that vertigo can be controlled in the long term using microdose gentamicin without a significant reduction in cochlear or vestibular function in most of the patients in our series. Our results are compared with the published literature examining transtympanic injection. In addition, the underlying science supporting this type of treatment is examined.
authors.affiliation: Department of Defense Spatial Orientation Center, Naval Medical Center San Diego, San Diego, California 92134-2200, USA. mehoffer@nmcsd.med.navy.mil
authors.forename: M E
authors.initials: ME
authors.lastname: Hoffer
authors.forename: R D
authors.initials: RD
authors.lastname: Kopke
authors.forename: P
authors.initials: P
authors.lastname: Weisskopf
authors.forename: K
authors.initials: K
authors.lastname: Gottshall
authors.forename: K
authors.initials: K
authors.lastname: Allen
authors.forename: D
authors.initials: D
authors.lastname: Wester
authors.forename: C
authors.initials: C
authors.lastname: Balaban
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002408:Catheters, Indwelling; D016503:Drug Delivery Systems / Q000295:instrumentation*; D005260:Female; D005500:Follow-Up Studies; D005839:Gentamicins / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy*; D012405:Round Window, Ear; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins